Evidence map›Paper›PMID 40521136›Full record

ReviewRegenerative therapy2025

Therapeutic roles of natural and engineered mesenchymal stem cells and extracellular vesicles in atopic dermatitis.

Tingting Ren, Kang He, Donghua Xu, Yuxiang Kong, Shuyue Jiang, Jinjin Chu, Yi Sun, Jie Zang, Zhenhua Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tingting RenDepartment of Dermatology, Weifang People's Hospital, Shandong Second Medical University, Weifang 261041, Shandong, China.
Kang HeSchool of Clinical Medicine, Shandong Second Medical University, Weifang 261000, Shandong, China.
Donghua XuCentral Laboratory, Weifang People's Hospital, Shandong Second Medical University, Weifang 261041, Shandong, China.
Yuxiang KongDepartment of Dermatology, Weifang People's Hospital, Shandong Second Medical University, Weifang 261041, Shandong, China.
Shuyue JiangSchool of Clinical Medicine, Shandong Second Medical University, Weifang 261000, Shandong, China.
Jinjin ChuCentral Laboratory, Weifang People's Hospital, Shandong Second Medical University, Weifang 261041, Shandong, China.
Yi SunDepartment of Dermatology, Weifang People's Hospital, Shandong Second Medical University, Weifang 261041, Shandong, China.
Jie ZangCentral Laboratory, Weifang People's Hospital, Shandong Second Medical University, Weifang 261041, Shandong, China.
Zhenhua WangDepartment of Dermatology, Weifang People's Hospital, Shandong Second Medical University, Weifang 261041, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic and inflammatory disease characterized by skin barrier destruction, sustained inflammation, and immune imbalance. Increasing evidence has suggested mesenchymal stem cells (MSCs) exhibit great potentials in treating AD due to the strong anti-inflammatory, immunomodulatory, and regenerative repair properties. As a cell-free nanocarrier, MSC-derived extracellular vesicles (MSC-EVs) play critical roles in mediating intercellular communications. Recent advance has suggested some bioengineering strategies have greatly improved the therapeutic potentials of MSCs and MSC-EVs in AD treatment, such as genetic reprogramming, biomimetic scaffold integration, and precision surface functionalization. In this comprehensive review, we systematically evaluate the current landscape of both natural and engineered MSCs and MSC-EVs to provide updated insights into the exploration of therapeutic strategies for AD.

Indexed as

Atopic dermatitisEngineering modificationExosomesExtracellular vesiclesMesenchymal stem cells

Identifiers

PMID40521136
PMCPMC12167125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.